{
    "clinical_study": {
        "@rank": "134453", 
        "arm_group": [
            {
                "arm_group_label": "Trial part 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Trial part 2", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of this trial is to investigate the safety,\n      tolerability, pharmacokinetics (the exposure of the trial drug in the body) and\n      pharmacodynamics (the effect of the investigated drug on the body) of insulin degludec\n      (insulin 454), an explorative formulation, not similar to the proposed commerical\n      formulation."
        }, 
        "brief_title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Explorative Formulation of Insulin Degludec", 
        "completion_date": {
            "#text": "April 2006", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 1", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  HEALTHY SUBJECTS:\n\n          -  Subjects will be healthy male subjects, who are considered to be generally healthy\n             based on an assessment of medical history, physical examination and clinical\n             laboratory data, as judged by the Investigator\n\n          -  Body mass index (BMI) between 18.0-27.0 kg/m^2 (both inclusive)\n\n          -  SUBJECTS WITH TYPE 1 AND TYPE 2 DIABETES:\n\n          -  Subjects will be male volunteers, who are considered to be generally healthy, except\n             for the underlying diabetes mellitus, based on an assessment of medical history,\n             physical examination and clinical laboratory data, as judged by the Investigator\n\n          -  Diagnosed with type 1 diabetes mellitus and treated with insulin for at least 12\n             months or diagnosed with type 2 diabetes mellitus for at least 12 months\n\n          -  Body Mass Index (BMI) between 18.0-27.0 kg/m^2 (both inclusive) for subjects with\n             type 1 diabetes or 25.0-35.0 kg/m^2 (both inclusive) for subjects with type 2\n             diabetes\n\n          -  Glycogylated haemoglobin (HbA1c) maximum 8.5 % based on central laboratory results\n\n          -  Subjects with type 2 diabetes must have been treated with insulin for the past 3\n             months prior to screening\n\n        Exclusion Criteria:\n\n          -  Participation in any other trials involving investigational products within 3 months\n             preceding the start of dosing\n\n          -  History of significant multiple drug allergies or with a known allergy to the trial\n             product or any medicine chemically related to the trial product, as judged by the\n             investigator\n\n          -  Hepatitis or carrier of the Hepatitis B surface antigen (HBsAg) or Hepatitis C\n             antibodies or a positive result to the test for human immunodeficiency (HIV)\n             antibodies\n\n          -  Any clinically significant abnormal haematology or biochemistry screening tests, as\n             judged by the investigator\n\n          -  Subjects who have donated any blood or plasma in the past month or in excess of 1000\n             ml within the 12 weeks preceding screening"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "64", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01865279", 
            "org_study_id": "NN5401-1718", 
            "secondary_id": "2005-003974-65"
        }, 
        "intervention": [
            {
                "arm_group_label": "Trial part 1", 
                "description": "Ascending single doses - 5 dose levels. Escalation to next dose level will be performed following evaluation of safety data.", 
                "intervention_name": "insulin degludec", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Trial part 1", 
                "description": "Ascending single doses - 5 dose levels", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Trial part 2", 
                "description": "A single dose corresponding to that of isophane human insulin", 
                "intervention_name": "insulin degludec", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Trial part 2", 
                "description": "A single dose of 0.4 IU/kg is administered to subjects with type 1 diabetes while a single dose of 0.6 IU/kg is administered to subjects with type 2 diabetes", 
                "intervention_name": "isophane human insulin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin", 
                "Insulin, NPH"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 27, 2013", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Neuss", 
                    "country": "Germany", 
                    "zip": "41460"
                }
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised, Double-blind, Placebo-controlled Single Dose, Dose Escalation Trial With Insulin 454 in Healthy Male Subjects, Followed by a Two-period Cross-over Trial With Insulin 454 and Insulatard\u00ae in Male Subjects With Type 1 and Type 2 Diabetes Mellitus", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Hanne Haahr", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2006", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Frequency of adverse events (trial part 1 only)", 
                "safety_issue": "No", 
                "time_frame": "From day prior to dosing and until 10-14 days after dosing"
            }, 
            {
                "measure": "Area under the glucose infusion rate curve (trial part 2 only)", 
                "safety_issue": "No", 
                "time_frame": "0-24 hours after dosing"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01865279"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Area under the serum insulin concentration curve", 
            "safety_issue": "No", 
            "time_frame": "0-72 hours after dosing"
        }, 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2005", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}